Edwards Lifesciences (EW) Proxy filing summary

Executive summary

• Focus on innovative solutions for cardiovascular disease, aiming to improve quality of life globally.

• Strategy centers on structural heart disease, pioneering new therapeutic categories, and addressing complex patient needs.

• Differentiated growth achieved through core innovations and expansion into emerging opportunities in heart therapies.

• Global scale with operations in over 100 countries and a resilient supply chain supported by 1,600+ engineers.

Voting matters and shareholder proposals

• Proposals include election of nine director nominees, advisory vote on executive compensation, ratification of independent auditor, and approval of amended long-term stock incentive plan.

Board of directors and corporate governance

• Board is 89% independent, with 33% women and 11% ethnically/racially diverse members; average age is 65.

• Directors bring expertise in medical technology, international business, innovation, finance, compliance, and risk oversight.

• Board composition and governance features have been enhanced, including majority voting and proxy access rights.

• Regular engagement with stockholders representing over 50% of outstanding shares.